Viscira® Delivers Record Business Results in 2014
- Category: Press Releases
- Published: Wednesday, 04 February 2015 15:01
Viscira, a leading provider of interactive, new-media communication solutions and software products for the life sciences industry, continued its stellar business performance in 2014. The company realized just over a 40% increase in gross revenue for FY 2014 as compared to FY 2013. Booked revenue grew by almost 50% over this same period.
This impressive growth was driven by the expansion of the company’s business volume with existing top-tier clients including Bristol-Myers Squibb, AbbVie, Janssen and Lilly. During 2014, Viscira also added several major new clients including Pfizer, AstraZeneca, Alexion, and Clovis Oncology. The company’s involvement with these clients included work on several pending new product launches.
Overall, the company continues to expand its roster of leading pharmaceutical, biotech and medical device customers, and has achieved solid penetration across major brands and therapeutic areas. Since 2011, Viscira has worked with 17 of the world’s top 25 pharmaceutical companies and has served over 135 unique brands.
With the opening of an office in London in 2014, Viscira has also expanded its global footprint and strengthened its local presence in the EU. These sales and marketing efforts have paid off, with revenue from global clients increasing by 42% for 2014 as compared to 2013.
“We are very pleased that we have been able to continue our business momentum with strong business results in 2014,” explains Dave Gulezian, President & CEO of Viscira. “Our success is driven by the talent, innovation and dedication of our diverse team. We look forward to our continued growth and evolution as a company in 2015 and beyond.”
Viscira has seen sales growth across their portfolio of products—from key software applications to digital multi-channel solutions like 3D animation. The company has also been effective in garnering digital agency of record status for an increasing numbers of brands, including brands within the oncology and rare disease areas.